PitchSend

Investor Presentaiton

23 Tumor Growth Inhibition (%) 100- 50- IDE397 Demonstrates Broad Efficacy across MTAP-deficient PDX Models Deep Regressions observed in NSCLC-squamous (LUSC), Esophageal and Bladder Cancers IDE397 Efficacy: 47 MTAP-/- PDX Models TGI with IDE397 (30mpk) in MTAP-/- PDX Panel 150- IDE397 In Vivo Efficacy in LUSC PDX Models Observed Tumor Regressions in 50% of LUSC PDX Models Vehicle IDE397 30mg/kg QD PDX1 750- PDX2 750- Pancreatic Head & Neck Gastric Bladder NSCLC-AC Esophageal NSCLC squamous SDMA Suppression in Residual Tumors* at End of Study 100- SDMA, Inhibition (%) Histology 1 Histology 2 Histology 3 Bladder NSCLC-AC IDEAYA Data; *2 of 8 LUSC unevaluable due to insufficient residual tumor burden Esophageal NSCLC squamous Mean Tumor Volume mm³ 500- Mean Tumor Volume mm³ 1200- 1000- 800- 600- 400- 200- 250- 0 7 PDX3 0 7 14 IDEAYA Data 14 Study Day 21 28 Study Day Mean Tumor Volume mm³ 21 28 0 Mean Tumor Volume mm³ 1500- 1000- 500- 500- 250- PDX4 0 T 0 14 21 7 14 21 28 Study Day 28 35 42 49 56 Study Day IDEAVA BIOSCIENCES

View entire presentation